Media & Resources

Final results confirm the innovative TB candidate vaccine’s efficacy level and acceptable safety profile in three-year clinical trial conducted in sub-Saharan African regions.

Technology transfer and international cooperation could lead to long-lived HIV protection for women and girls in developing countries.

Partners in five countries will discover and develop monoclonal antibodies to treat critical illness from snake venom, which harms nearly 3 million people each year.

Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein.

David L. Blumberg, Jim Connolly, John Nkengasong, John Shiver, Anne Simonds, and Rajeev Venkayya join IAVI Board in 4Q 2018.

Collaboration to develop optimal combination of HIV-specific antibodies and ensure that cost is not a barrier to access.

Phase I trial to evaluate safety and immunogenicity of vaccine candidate engineered to elicit targeted immune response against HIV.

Data from two Phase II clinical trials conducted by Aeras and partners indicate promise for future of TB vaccine development.